NVO
Back to the hiring game
Novo Nordisk is swinging the scissors one minute and reopening the job board the next. The company’s restructuring — led by CEO Mike Doustdar — is meant to streamline the organization and make Novo more competitive after it lost ground in the obesity-drug market.
That’s the corporate version of a garage cleanout where you accidentally throw out the good cables. The goal is efficiency, but the process is also shaking up the roster.
The exits are getting attention
One of the most notable departures is scientist Lotte Bjerre Knudsen, a key figure in the development of GLP-1 therapies. When someone with that kind of legacy leaves, it’s not just an HR footnote — it’s a signal that the company is actively reshaping its identity, not just trimming costs.
Why investors should care
The stock is still down roughly 20% this year, even after a 3.5% pop Thursday. That tells you the market isn’t just watching headcount math; it’s watching whether Novo can actually turn this reorg into a comeback in obesity drugs.
Big picture: Novo is trying to look leaner, hungrier, and more competitive. Whether that becomes a reset or just a messy chapter depends on what it hires — and what it loses — next.